Skip to main content

CCTG Connection



Published:
Category: Group updates
American Association for Cancer Research Scientist-Survivor Program

Call for Applications: American Association for Cancer Research Scientist↔Survivor Program® 

Read More

Published:
Category: Group updates
IT update New login screen for users

CCTG is upgrading the login platform to Auth0 by Okta for a more secure and seamless login experience. The new login screen is designed to be simple and user-friendly, allowing users to log in using existing credentials. This change ensures faster, more reliable access to your account with fewer sign ins, while keeping your data safe.

Read More

Published:
Category: Publications
Publication: Statistical
Joint Analysis of Longitudinal Proportional Measurements and Survival Times Based on Generalized Mean-Variance Mixed Model and Cox Proportional Hazards Model
 
In cancer clinical trials and other types of medical studies, longitudinal data are often observed in conjunction with survival data.
Read More

Published:
Category: Trials
Closed to Accrual: ME.15

The ME.15 (MelMarT-II) phase III randomized control trial investigating 1cm vs 2cm wide excision margins for primary cutaneous melanoma has closed to accrual after reaching the accrual target of 3000 patients enrolled. This study is investigating the use of smaller surgical margins to reduce the extent of surgery in Stage 2 melanoma patient and improve quality of lift.

Read More



Published:
Category: Group updates
2024 Annual Report
The CCTG 2024 Annual Report is now live! 
 
2024 was a highly eventful year for the group, marked by both challenges and significant achievements. The group surpassed expectations in trial activation, launching 18 new studies across early and late phase programs—exceeding our annual target. Funding activity was also strong, with 17 applications submitted and seven successfully awarded, securing $5.9 million in support.
Read More

Published:
Category: Publications
Publication: HNC2 (primary)
HNC2 (NRG-HN004): Radiotherapy with cetuximab or durvalumab for locoregionally advanced head and neck cancer in patients with a contraindication to cisplatin 
Management of patients with locoregionally advanced head and neck squamous cell carcinoma when cisplatin is contraindicated is controversial.
Read More

Published:
Category: Publications
Publications: General Review
Two general publication, the first is looking at the financial difficulty among patients with cancer participating in clinical trials, the other is an evaluation of the Canadian Remote Access Framework for Clinical Trials (CRAFT) pilot. Read More

Published:
Category: Publications
Publication: secondary analysis CX5 and CO26
Secondary analysis: CX5 surgical approach analysis and the CO26 cost utility analysis Read More